Imperial College London

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.

A new total-body PET scanner that is quicker for the patient and produces higher quality images for faster and earlier diagnosis and treatment of illnesses like cancer and heart conditions, was unveiled by Ministers in London yesterday (Wednesday 27 November).

Imperial, the leading global science university, is achieving a major step up in its life sciences capacity at its White City Deep Tech Campus through a major new joint venture with Bruntwood SciTech.

London was the epicentre of the life science industry during London Life Sciences Week last week. The 2024 edition marked a significant step forward in both the quality and quantity of events and interactions.

RSSL has today announced that it has secured funding from Innovate UK, the UK’s national innovation agency, to establish the country’s first Novel Foods Expert Network for Regulatory Challenges (NFX UK).

Precision BioSearch is proud to support the Pioneer Group Launch Accelerator Programme for the second consecutive year, equipping the UK and Ireland’s most promising biotech founders with the skills to build and scale high-performing teams.

 This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.

A new partnership with ARC West London, designed to support innovators across AI, life sciences, robotics and digital industries to scale, bolstering the West London life sciences ecosystem.

The global life science investment and media community are heading to the JPM Healthcare Conference next week and we’ll be keeping an eye on announcements and grants that impact our industry.

When comparing the UK’s RNA manufacturing capability now, to that of before COVID-19, it is obvious that great advancements have been made. Abby Clark, Senior Manufacturing Programme Executive at the BIA, reflects on the past (nearly) five years and highlights recent work in the area.  

Pharma multinational bets on candidates invented by GLP-1 pioneer Prof Steve Bloom to propel it into the race for next-generation obesity treatments.